# Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

> **NCT06910072** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 32 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)
- Neoadjuvant Therapy

## Interventions

- **DRUG:** paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

## Key facts

- **NCT ID:** NCT06910072
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910072, "Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06910072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*